Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VTYX |
---|---|---|
09:32 ET | 17684 | 3.78 |
09:34 ET | 150 | 3.8 |
09:36 ET | 7885 | 3.81 |
09:38 ET | 322 | 3.8014 |
09:39 ET | 1408 | 3.79 |
09:41 ET | 400 | 3.8 |
09:43 ET | 300 | 3.81 |
09:45 ET | 1600 | 3.81 |
09:52 ET | 663 | 3.8 |
09:54 ET | 1154 | 3.805 |
09:56 ET | 3014 | 3.81 |
09:57 ET | 1900 | 3.815 |
09:59 ET | 600 | 3.815 |
10:01 ET | 2200 | 3.815 |
10:03 ET | 5532 | 3.81 |
10:06 ET | 800 | 3.815 |
10:08 ET | 16154 | 3.86 |
10:10 ET | 1288 | 3.86 |
10:12 ET | 2244 | 3.86 |
10:15 ET | 2000 | 3.86 |
10:17 ET | 2100 | 3.86 |
10:19 ET | 17521 | 3.855 |
10:21 ET | 7782 | 3.885 |
10:24 ET | 14015 | 3.94 |
10:26 ET | 4220 | 3.935 |
10:28 ET | 400 | 3.935 |
10:30 ET | 2000 | 3.9301 |
10:32 ET | 5000 | 3.905 |
10:33 ET | 4783 | 3.895 |
10:35 ET | 2132 | 3.885 |
10:37 ET | 100 | 3.89 |
10:39 ET | 215 | 3.895 |
10:42 ET | 4089 | 3.89 |
10:44 ET | 5674 | 3.8799 |
10:46 ET | 2000 | 3.8799 |
10:48 ET | 1400 | 3.8788 |
10:50 ET | 200 | 3.875 |
10:51 ET | 1298 | 3.89 |
10:53 ET | 616 | 3.89 |
10:55 ET | 4412 | 3.88 |
10:57 ET | 100 | 3.88 |
11:00 ET | 4354 | 3.885 |
11:02 ET | 1400 | 3.88 |
11:04 ET | 200 | 3.875 |
11:06 ET | 400 | 3.87 |
11:08 ET | 9846 | 3.84 |
11:09 ET | 10231 | 3.84 |
11:13 ET | 1500 | 3.845 |
11:15 ET | 600 | 3.845 |
11:18 ET | 900 | 3.845 |
11:22 ET | 600 | 3.845 |
11:24 ET | 200 | 3.845 |
11:26 ET | 1305 | 3.86 |
11:27 ET | 100 | 3.86 |
11:29 ET | 100 | 3.86 |
11:31 ET | 8218 | 3.83 |
11:36 ET | 1874 | 3.82 |
11:38 ET | 3204 | 3.8 |
11:40 ET | 3291 | 3.8 |
11:42 ET | 2895 | 3.8 |
11:44 ET | 1215 | 3.79 |
11:45 ET | 4676 | 3.8 |
11:47 ET | 1500 | 3.7988 |
11:49 ET | 1707 | 3.79 |
11:51 ET | 2865 | 3.79 |
11:54 ET | 2651 | 3.79 |
11:56 ET | 11171 | 3.845 |
11:58 ET | 610 | 3.85 |
12:00 ET | 5177 | 3.86 |
12:02 ET | 4905 | 3.85 |
12:03 ET | 2217 | 3.83 |
12:05 ET | 1200 | 3.82 |
12:07 ET | 3514 | 3.81 |
12:09 ET | 78157 | 3.86 |
12:12 ET | 1000 | 3.85 |
12:14 ET | 800 | 3.84 |
12:16 ET | 5609 | 3.84 |
12:18 ET | 1098 | 3.83 |
12:20 ET | 51820 | 3.84 |
12:21 ET | 1690 | 3.84 |
12:23 ET | 1323 | 3.845 |
12:25 ET | 2000 | 3.83 |
12:27 ET | 103123 | 3.83 |
12:30 ET | 2204 | 3.83 |
12:32 ET | 69578 | 3.83 |
12:34 ET | 35627 | 3.82 |
12:36 ET | 52627 | 3.81 |
12:38 ET | 2337 | 3.8 |
12:39 ET | 2168 | 3.8 |
12:41 ET | 2106 | 3.79 |
12:43 ET | 4610 | 3.79 |
12:45 ET | 506651 | 3.82 |
12:48 ET | 9505 | 3.87 |
12:50 ET | 3300 | 3.83 |
12:52 ET | 1693 | 3.81 |
12:54 ET | 24638 | 3.82 |
12:56 ET | 1640 | 3.81 |
12:57 ET | 2633 | 3.8 |
12:59 ET | 2888 | 3.8 |
01:01 ET | 2000 | 3.8 |
01:03 ET | 2285 | 3.8 |
01:06 ET | 5614 | 3.81 |
01:08 ET | 1100 | 3.8 |
01:10 ET | 2500 | 3.8 |
01:12 ET | 2182 | 3.79 |
01:14 ET | 1475 | 3.78 |
01:15 ET | 2998 | 3.79 |
01:17 ET | 1360 | 3.79 |
01:19 ET | 31176 | 3.82 |
01:21 ET | 1035 | 3.82 |
01:24 ET | 1775 | 3.825 |
01:26 ET | 2290 | 3.82 |
01:28 ET | 3677 | 3.8391 |
01:30 ET | 9020 | 3.81 |
01:32 ET | 3050 | 3.8099 |
01:33 ET | 1183 | 3.8 |
01:35 ET | 2400 | 3.8 |
01:37 ET | 1311 | 3.8 |
01:39 ET | 2143 | 3.81 |
01:42 ET | 52400 | 3.81 |
01:44 ET | 1339 | 3.81 |
01:46 ET | 1500 | 3.8 |
01:48 ET | 3701 | 3.8 |
01:50 ET | 1700 | 3.8 |
01:51 ET | 4486 | 3.81 |
01:53 ET | 299035 | 3.835 |
01:55 ET | 1090 | 3.84 |
01:57 ET | 3077 | 3.82 |
02:00 ET | 3013 | 3.835 |
02:02 ET | 2734 | 3.84 |
02:04 ET | 2075 | 3.82 |
02:06 ET | 2734 | 3.83 |
02:08 ET | 2980 | 3.82 |
02:09 ET | 3658 | 3.82 |
02:11 ET | 2187 | 3.82 |
02:13 ET | 3756 | 3.82 |
02:15 ET | 3210 | 3.82 |
02:18 ET | 7433 | 3.81 |
02:20 ET | 5602 | 3.81 |
02:22 ET | 4100 | 3.82 |
02:24 ET | 3205 | 3.81 |
02:26 ET | 5759 | 3.8 |
02:27 ET | 21025 | 3.825 |
02:29 ET | 6101 | 3.81 |
02:31 ET | 6587 | 3.81 |
02:33 ET | 2275 | 3.81 |
02:36 ET | 10525 | 3.8 |
02:38 ET | 2359 | 3.79 |
02:40 ET | 1920 | 3.79 |
02:42 ET | 2742 | 3.79 |
02:44 ET | 1760 | 3.78 |
02:45 ET | 2658 | 3.78 |
02:47 ET | 2838 | 3.79 |
02:49 ET | 4027 | 3.79 |
02:51 ET | 2972 | 3.79 |
02:54 ET | 3800 | 3.78 |
02:56 ET | 4082 | 3.79 |
02:58 ET | 2942 | 3.79 |
03:00 ET | 3036 | 3.785 |
03:02 ET | 2092 | 3.78 |
03:03 ET | 7872 | 3.79 |
03:05 ET | 4089 | 3.78 |
03:07 ET | 16899 | 3.78 |
03:09 ET | 2900 | 3.78 |
03:12 ET | 16152 | 3.78 |
03:14 ET | 10472 | 3.75 |
03:16 ET | 27208 | 3.77 |
03:18 ET | 3758 | 3.76 |
03:20 ET | 21510 | 3.74 |
03:21 ET | 3791 | 3.73 |
03:23 ET | 4861 | 3.73 |
03:25 ET | 27135 | 3.71 |
03:27 ET | 2986 | 3.71 |
03:30 ET | 4316 | 3.71 |
03:32 ET | 5773 | 3.71 |
03:34 ET | 4110 | 3.71 |
03:36 ET | 5327 | 3.7 |
03:38 ET | 10447 | 3.7 |
03:39 ET | 7199 | 3.7 |
03:41 ET | 16482 | 3.71 |
03:43 ET | 9589 | 3.72 |
03:45 ET | 25812 | 3.77 |
03:48 ET | 13822 | 3.74 |
03:50 ET | 14321 | 3.75 |
03:52 ET | 18489 | 3.74 |
03:54 ET | 15800 | 3.745 |
03:56 ET | 48978 | 3.755 |
03:57 ET | 30214 | 3.775 |
03:59 ET | 46978 | 3.74 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ventyx Biosciences Inc | 270.1M | -1.1x | --- |
ESSA Pharma Inc | 271.6M | -11.0x | --- |
Inozyme Pharma Inc | 273.0M | -3.2x | --- |
RAPT Therapeutics Inc | 274.2M | -2.5x | --- |
Opthea Ltd | 277.1M | -1.3x | --- |
Monte Rosa Therapeutics Inc | 281.4M | -2.0x | --- |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $263.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.29 |
Book Value | $4.12 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.